Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin
- PMID: 16194205
- DOI: 10.1111/j.1538-7836.2005.01479.x
Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin
Abstract
Objective: The role of vitronectin (VN) in thrombosis is not fully understood, primarily because this adhesive glycoprotein not only stabilizes plasminogen activator inhibitor 1 (PAI-1) and thus protects fibrin from premature lysis, but also because it binds to platelet integrins and may influence platelet aggregation. The absence of quantitative approaches to characterize the thrombi formed in animal models under different conditions further complicates this analysis.
Methods: In this report, we describe a more comprehensive approach to assess the stability of thrombi formed in mice deficient in PAI-1 (PAI-1(-/-)), VN (VN(-/-)) or both (PAI-1(-/-)/VN(-/-)).
Results: We observed that all deficient mice developed unstable thrombi compared with wild type (WT) mice. Thus, only 31% of the thrombi formed in WT mice were unstable compared with 74% of PAI-1(-/-), 80% of VN(-/-), and 87% of PAI-1(-/-)/VN(-/-) mice. In this regard, the average number of emboli per WT mouse was significantly lower (0.55) compared with VN(-/-) (2.66), PAI-1(-/-) (2.1), and VN(-/-)/PAI-1(-/-) (2.35) mice. Finally, the total duration of complete vascular occlusion was higher and the rate of vascular patency was lower in the WT mice compared with the deficient mice.
Conclusions: Taken together, these observations indicate that the thrombotic phenotype of mice with a combined deficiency in PAI-1 and VN does not differ significantly from the phenotype of mice with deficiencies in only PAI-1 or VN. This observation suggests that PAI-1 and VN may influence thrombus stability by regulating a common pathway.
Similar articles
-
Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice.Circulation. 2001 Jan 30;103(4):576-83. doi: 10.1161/01.cir.103.4.576. Circulation. 2001. PMID: 11157725
-
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.Blood. 2000 Jan 15;95(2):577-80. Blood. 2000. PMID: 10627465
-
Vitronectin inhibits the thrombotic response to arterial injury in mice.Blood. 1999 Mar 15;93(6):1825-30. Blood. 1999. PMID: 10068653
-
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.Biol Chem. 2002 Jul-Aug;383(7-8):1143-9. doi: 10.1515/BC.2002.125. Biol Chem. 2002. PMID: 12437099 Review.
-
Regulation of cell adhesion by PAI-1.APMIS. 1999 Jan;107(1):54-61. doi: 10.1111/j.1699-0463.1999.tb01526.x. APMIS. 1999. PMID: 10190280 Review.
Cited by
-
Bone Matrix Non-Collagenous Proteins in Tissue Engineering: Creating New Bone by Mimicking the Extracellular Matrix.Polymers (Basel). 2021 Mar 30;13(7):1095. doi: 10.3390/polym13071095. Polymers (Basel). 2021. PMID: 33808184 Free PMC article. Review.
-
Platelet adhesion under flow.Microcirculation. 2009 Jan;16(1):58-83. doi: 10.1080/10739680802651477. Microcirculation. 2009. PMID: 19191170 Free PMC article. Review.
-
An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode.J Exp Med. 2015 Jun 1;212(6):905-25. doi: 10.1084/jem.20141268. Epub 2015 May 11. J Exp Med. 2015. PMID: 25964372 Free PMC article.
-
Serum vitronectin levels in patients with Behçet's disease.Inflamm Res. 2012 Nov;61(11):1241-6. doi: 10.1007/s00011-012-0521-z. Epub 2012 Jul 19. Inflamm Res. 2012. PMID: 22810367
-
Vitronectin promotes immunothrombotic dysregulation in the venular microvasculature.Front Immunol. 2023 Feb 8;14:1078005. doi: 10.3389/fimmu.2023.1078005. eCollection 2023. Front Immunol. 2023. PMID: 36845099 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous